Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 24, 2026
CRMG ETF Jumps +58% in 30 Days on Salesforce's Strong AI Results

CRMG ETF Jumps +58% in 30 Days on Salesforce's Strong AI Results

Key Takeaways

  • CRMG is a single-stock leveraged exchange-traded fund (ETF) that targets 2x (200%) the daily return of CRM, so its performance is dominated by Salesforce's share price.
  • The fund has climbed roughly +58% over the trailing 30 days, from about $5.94 to $9.39.
  • The advance was driven by Salesforce's blowout fiscal second-quarter earnings, which showcased accelerating AI monetization and lifted full-year guidance.
  • Over the trailing quarter, CRMG has rebounded about +91% from a June low following a sharp enterprise-software selloff.
  • Because it resets leverage daily, CRMG can diverge from a simple 2x Salesforce return over time and is designed for short-term, tactical use.

Understanding CRMG's Leveraged Exposure to Salesforce

CRMG is an actively managed, single-stock leveraged ETF that seeks daily investment results equal to 200% of the daily percentage change in the common stock of Salesforce (NYSE: CRM), before fees and expenses. Rather than holding Salesforce shares directly, the fund pursues its objective through a small portfolio of swap agreements with major financial institutions, with Treasury money-market instruments held as collateral. The fund carries a total expense ratio of approximately 0.75% and is non-diversified.

This structure makes CRMG effectively a leveraged expression of a single company's stock. Its exposure is not a broad basket of industries but nearly 100% synthetic exposure to Salesforce, so the ETF's recent performance is almost entirely a function of one name. For investors, that concentration amplifies both gains and losses and introduces daily-reset compounding effects that can cause multi-day returns to deviate from twice the underlying's move. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Price Moves: +58% Over 30 Days, +91% Over Quarter

Over the trailing 30 days, CRMG rose approximately +58%, from a close near $5.94 to about $9.39. The advance was not gradual: most of the gain arrived in a single, gap-up session after the company's fiscal second-quarter report, when the fund jumped roughly 44% in one day as Salesforce shares surged about 22.6%. The move was trend-driven and volatile rather than range-bound.

Looking at the trailing quarter, CRMG has climbed roughly +91% from a level near $4.92 three months earlier. The path was uneven. The fund entered the period near $7.48, slid to a trough around $3.78 by mid-June during a broad enterprise-software selloff, and then staged a powerful recovery that accelerated sharply after the August earnings report.

Drivers Behind the Recent Gains

The dominant catalyst was Salesforce's fiscal second-quarter report, which reset sentiment across the enterprise-software complex. The company reported adjusted earnings per share (EPS) of $5.90, far above the $3.27 consensus, on revenue of $11.35 billion, up 11% year over year. Free cash flow rose 81% to $1.1 billion, and management raised full-year adjusted EPS guidance to roughly $16.67–$16.71 from about $14.06–$14.12. The EPS figure included a gain tied to Salesforce's stake in Anthropic, though the jump in free cash flow pointed to genuine operating momentum.

The AI narrative drove the reaction. Agentforce, Salesforce's agentic AI platform, reached $1.5 billion in annual recurring revenue (ARR), up 240% year over year, while the Data 360 platform's ARR roughly tripled. Salesforce also announced "Claudeforce," an expanded partnership with Anthropic to integrate Claude's reasoning into Salesforce workflows. These results countered earlier fears that generative AI would undermine software demand, and Salesforce stock jumped about 22.6% in a single session. With its 2x daily leverage, CRMG amplified that move into a roughly 44% single-day gain.

Quarter-Long Recovery Explained

The broader three-month trend reflects a sharp rotation in enterprise software. During the first half of the year, Salesforce and many software peers sold off on fears that AI agents would reduce demand for traditional seat-based software — a narrative sometimes described as the "SaaS apocalypse." Salesforce fell sharply through June and became one of the weakest large-cap performers, and CRMG, as a leveraged vehicle, declined even more dramatically.

The August earnings report reversed that narrative by demonstrating that AI had become a measurable revenue driver rather than a threat. Combined with short-covering — short interest in Salesforce had built up during the selloff — and renewed institutional buying in software, this powered a multi-week recovery that lifted CRMG far above its June lows.

CRMG ETF Outlook: What Investors Should Watch Next

Going forward, CRMG's path will remain tied to Salesforce and, more broadly, to the enterprise-AI spending cycle. Key factors to monitor include the pace of Agentforce adoption and renewal activity, the rollout of the Claudeforce integration, and whether Salesforce can sustain double-digit revenue growth and margin expansion in upcoming quarters. Macroeconomic conditions — interest-rate expectations, inflation, and corporate IT budgets — will also influence the software sector's valuation multiple.

Investors should also account for the structural risks of a leveraged single-stock ETF. Daily rebalancing can produce compounding losses in choppy markets, and a decline in the underlying security could result in outsized losses. The next Salesforce earnings report, updates to full-year guidance, and broader software-sector sentiment will be the most important near-term catalysts for CRMG. From what I see, this is important because the daily reset feature requires close attention to short-term moves rather than long-term holding assumptions.

Using Tickeron’s AI Screener for ETF Research

I often turn to Tickeron’s AI Screener when evaluating leveraged products like CRMG. The platform helps scan for momentum shifts across ETFs and sectors using technical and fundamental filters, which can streamline the process of comparing opportunities in volatile names. Explore the AI Screener to refine your own watchlist and research workflow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRMG

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


CRMG's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for CRMG moved out of overbought territory on September 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 instances where the indicator moved out of the overbought zone. In 5 of the 5 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMG as a result. In 21 of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for CRMG turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CRMG broke above its upper Bollinger Band on August 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +13.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMG advanced for three days, in 68 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 22 of 28 cases where CRMG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Industry description

The investment seeks daily levered investment results, before fees and expenses, of two times (200%) of the daily percentage change in the price of the common stock of CRM. The fund is an actively managed ETF. It invests at least 80% of its net assets (plus borrowings for investment purposes) in financial instruments with economic characteristics that, in combination, provide 200% daily leveraged exposure to the price of CRM, consistent with the fund’s investment objective. The fund is non-diversified.
View a ticker or compare two or three
CRMG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
www.ThemesETFs.com
Interact to see
Advertisement
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.